JUDGMENT (Oral)

1. The disputes between the plaintiffs and all the defendants stand settled. The plaintiffs and the defendants are represented by their respective learned Counsel. The terms of the settlement are as under:

The Settlement Agreement dated 21st February 2023 with Defendant 1:

"1. The Defendant No. 1 acknowledges the validity of the Plaintiff No. 1's patent, IN 247381 during its term which expired on September 17, 2022.

2. The Defendant No. 1 confirms that till date, they never manufactured, sold or exported `Apixaban' and they have further discontinued using, promoting, distributing, offering for sale, or otherwise dealing in `Apixaban' and/or any of its pharmaceutically acceptable salts in any form (API or finished formulation under any the brand name whatsoever).

3. The Defendant No. 1, neither sold any unit of Apixaban to any third party, nor made/earned any profit(s) out of the sale of Apixaban, in any form till date. The undertakings given above by the Defendant No. 1 shall be binding henceforth on the Defendant No. 1, their associates, representatives, successors, partners, agents, employees, affiliates and assignees-in-business.

4. That the Defendant No. 1 undertake